Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient.

Bjoern Chapuy, Margaretha G. M. Roemer, Chip Stewart, Yuxiang Tan, Ryan P. Abo, Liye Zhang, Andrew J. Dunford, David M. Meredith, Aaron R. Thorner, Ekaterina S. Jordanova, Gang Liu, Friedrich Feuerhake, Matthew D. Ducar, Gerald Illerhaus, Daniel Gusenleitner, Erica A. Linden, Heather H. Sun, Heather Homer, Miyuki Aono, Geraldine S. Pinkus, Azra H. Ligon, Keith L. Ligon, Judith A. Ferry, Gordon J. Freeman, Paul van Hummelen, Todd R. Golub, Gad Getz, Scott J. Rodig, Daphne de Jong, Stefano Monti, Margaret A. Shipp, Targetable genetic features of primary testicular and primary central nervous system lymphomas Blood. ,vol. 127, pp. 869- 881 ,(2014) , 10.1182/BLOOD-2015-10-673236

W. K. Kremers, H. C. Devarbhavi, R. H. Wiesner, R. A. F. Krom, W. R. Macon, T. M. Habermann, Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. American Journal of Transplantation. ,vol. 6, pp. 1017- 1024 ,(2006) , 10.1111/J.1600-6143.2006.01294.X

Eric Chak, Sammy Saab, Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review Liver International. ,vol. 30, pp. 1247- 1258 ,(2010) , 10.1111/J.1478-3231.2010.02303.X

Alexander M. Lesokhin, Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok, On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine. ,vol. 7, ,(2015) , 10.1126/SCITRANSLMED.3010274

Douglas Hanahan, Robert A. Weinberg, Hallmarks of cancer: the next generation. Cell. ,vol. 144, pp. 646- 674 ,(2011) , 10.1016/J.CELL.2011.02.013

Michael R. Green, Scott Rodig, Przemyslaw Juszczynski, Jing Ouyang, Papiya Sinha, Evan O'Donnell, Donna Neuberg, Margaret A. Shipp, Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy Clinical Cancer Research. ,vol. 18, pp. 1611- 1618 ,(2012) , 10.1158/1078-0432.CCR-11-1942

Lakshmi Nayak, Fabio M. Iwamoto, Ann LaCasce, Srinivasan Mukundan, Margaretha G. M. Roemer, Bjoern Chapuy, Philippe Armand, Scott J. Rodig, Margaret A. Shipp, PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma Blood. ,vol. 129, pp. 3071- 3073 ,(2017) , 10.1182/BLOOD-2017-01-764209

Thomas Menter, Darius Juskevicius, Mary Alikian, Juerg Steiger, Stephan Dirnhofer, Alexandar Tzankov, Kikkeri N. Naresh, Mutational landscape of B-cell post-transplant lymphoproliferative disorders British Journal of Haematology. ,vol. 178, pp. 48- 56 ,(2017) , 10.1111/BJH.14633

Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H Johnson, Van Anh Trinh, Chrystia M Zobniw, Heather Lin, Michael K Wong, Maen Abdelrahim, A Osama Gaber, Maria E Suarez-Almazor, Adi Diab, None, Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature Journal for ImmunoTherapy of Cancer. ,vol. 7, pp. 106- ,(2019) , 10.1186/S40425-019-0585-1

Josefine Radke, Arend Koch, Fabienne Pritsch, Elisa Schumann, Martin Misch, Claudia Hempt, Klaus Lenz, Franziska Löbel, Fabienne Paschereit, Frank L. Heppner, Peter Vajkoczy, Randi Koll, Julia Onken, Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients Acta neuropathologica communications. ,vol. 7, pp. 1- 9 ,(2019) , 10.1186/S40478-019-0745-Z